In one paragraphArticle in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
Alessandro FerrandoDepartment of Clinical and Biological Sciences, University of Turin, AOU San Luigi Gonzaga, Orbassano, 10043 Turin, Italy.ORCID 0009-0000-6304-9782 Johanna UmurungiDepartment of Clinical and Biological Sciences, University of Turin, AOU San Luigi Gonzaga, Orbassano, 10043 Turin, Italy.ORCID 0009-0006-1483-4171 Alice Costanza DanzeroDepartment of Clinical and Biological Sciences, University of Turin, AOU San Luigi Gonzaga, Orbassano, 10043 Turin, Italy.ORCID 0009-0007-8657-1187 Antonio FrolliDepartment of Clinical and Biological Sciences, University of Turin, AOU San Luigi Gonzaga, Orbassano, 10043 Turin, Italy.
Rita VaccaDepartment of Clinical and Biological Sciences, University of Turin, AOU San Luigi Gonzaga, Orbassano, 10043 Turin, Italy.
Arianna SaviDivision of Hematology, AO Ordine Mauriziano di Torino, 10128 Turin, Italy.
Giovanni FornariDepartment of Clinical and Biological Sciences, University of Turin, AOU San Luigi Gonzaga, Orbassano, 10043 Turin, Italy.
Beatrice SaniDepartment of Clinical and Biological Sciences, University of Turin, AOU San Luigi Gonzaga, Orbassano, 10043 Turin, Italy.ORCID 0009-0004-1437-7201 Simone RoccoDepartment of Clinical and Biological Sciences, University of Turin, AOU San Luigi Gonzaga, Orbassano, 10043 Turin, Italy.ORCID 0000-0001-8805-959X Barbara PergolizziDepartment of Clinical and Biological Sciences, University of Turin, AOU San Luigi Gonzaga, Orbassano, 10043 Turin, Italy.ORCID 0000-0003-4686-0068 Carmen FavaDepartment of Clinical and Biological Sciences, University of Turin, AOU San Luigi Gonzaga, Orbassano, 10043 Turin, Italy.ORCID 0000-0002-4896-981X Cristina PanuzzoDepartment of Clinical and Biological Sciences, University of Turin, AOU San Luigi Gonzaga, Orbassano, 10043 Turin, Italy.
Jessica PetitiDepartment of Clinical and Biological Sciences, University of Turin, AOU San Luigi Gonzaga, Orbassano, 10043 Turin, Italy.ORCID 0000-0001-8640-2462 Daniela CilloniDepartment of Clinical and Biological Sciences, University of Turin, AOU San Luigi Gonzaga, Orbassano, 10043 Turin, Italy.ORCID 0000-0001-6346-4791 Funding
Astellas Pharma SPA ISR005958
6 · The paper itselfAbstract
The FLT3-ITD mutation is a critical prognostic marker in acute myeloid leukemia (AML) and recent clinical trials demonstrate that FLT3-based measurable residual disease (MRD) is both prognostic and predictive, guiding therapeutic interventions in intensive and post-transplant settings. Conventional detection methods lack the sensitivity required for effective MRD monitoring. We developed a patient-specific droplet digital PCR (ddPCR) approach achieving analytical sensitivity of 10
Indexed as
fms-Like Tyrosine Kinase 3Leukemia, Myeloid, AcutePolymerase Chain ReactionHumansMutationNeoplasm, ResidualRecurrenceFLT3 protein, humanfms-Like Tyrosine Kinase 3AMLclonal dynamicddPCRFLT3-ITDMRD
Identifiers
PMID41828696
PMCPMC12985544
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390